Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 21, 2016; 22(47): 10432-10439
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Table 1 Baseline characteristics of the patients n (%)
Variables | |
Female | 18 (54.4) |
Mean age | 13 |
Extent of disease | |
Proctitis | 0 |
Left-side colitis | 12 (30) |
Extensive colitis | 21 (70) |
Current smokers | 2 (11.1) |
Endoscopic Mayo score 2-3 | 30 (100) |
No previous endoscopy | 3 |
Clinical situation before golimumab | |
Mild-remission | 5 (15.2) |
Moderate-severe | 28 (84.8) |
Golimumab indication | |
Induction of remission | 28 (84.8) |
Maintenance of remission | 3 (9.1) |
Extra-intestinal manifestations | 2 (11.1) |
Previous anti-TNF use | 24 (72.7) |
Use of > 1 anti-TNF | 16 (48.5) |
Previous anti-TNF failure | |
Primary non-responders | 6 (25) |
Loss of response | 14 (58.3) |
Infusion reaction | 4 (16.6) |
Previous steroid consumption (31 patients had previous steroid consumption) | |
Steroid-refractory | 7 (27.3) |
Steroid-dependent | 24 (72.7) |
Use of steroids at induction | 25 (75.7) |
Associated immunosuppressors | 12 (36.6) |
Azathioprine | 11 (33.3) |
Tacrolimus | 1 (3) |
- Citation: Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439
- URL: https://www.wjgnet.com/1007-9327/full/v22/i47/10432.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i47.10432